Announcements Trials

Browse Landscape

Phase

Phase 2 3 Phase 3 1 Phase 1/2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 5 CNS 5 Plasma cell 3 Genitourinary 3 Breast 3 Gynecologic 2 Tumor-Agnostic 1 Thoracic 1 Other neoplasm 1 Other hematologic neoplasm 1 Myeloid 1 Lymphoid 1 Gastrointestinal 1

Conditions

CLDN18.2-positive Gastric Adenocarcinoma 1

Interventions

Gemcitabine 218 Fluorouracil 142 Oxaliplatin 132 Capecitabine 122 pembrolizumab 113 Irinotecan 110 Leucovorin 104 Bevacizumab 98 Nivolumab 80 Cisplatin 80 130-nm albumin-bound paclitaxel 80 Cetuximab 79 Radiotherapy 78 Albumin-Bound Paclitaxel 59 Sorafenib 56 Paclitaxel 53 Cyclophosphamide 50 Carboplatin 47 Magnetic Resonance Spectroscopy 44 Specimen Handling 39 Docetaxel 37 Taxes 36 fludarabine 34 Radiation 34 durvalumab 33 Ipilimumab 33 Erlotinib Hydrochloride 33 Biopsy 33 Radiosurgery 27 Folfox protocol 27

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Zoledronic Acid × Gastrointestinal × Clear all

NCT01671774 2024-11-14

PILOT

Astellas Pharma Inc

Phase 1 Completed

Gastrointestinal

CLDN18.2-positive Gastric Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡